Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole
Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependenc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2021-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860120184946688 |
|---|---|
| author | O. D. Lopina B. K. Nurgalieva T. L. Lapina |
| author_facet | O. D. Lopina B. K. Nurgalieva T. L. Lapina |
| author_sort | O. D. Lopina |
| collection | DOAJ |
| description | Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatment for such acid-dependent diseases as gastroesophageal reflux disease and peptic ulcer. This makes rabeprazole (Pariet) a preferred drug in course and maintenance therapies for acid-dependent diseases, as well as in H. pylori eradication.Conclusion. The rabeprazole properties of high acid suppression potential, persistent antisecretory effect from first day of therapy, non-enzymatic metabolism and pleiotropic action determine its high efficacy in treatment for a wide range of acid-dependent diseases at a minimal risk of drug interaction. |
| format | Article |
| id | doaj-art-37b975fe202a4b3bbf611332d1e02864 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2021-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-37b975fe202a4b3bbf611332d1e028642025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732021-12-01314556310.22416/1382-4376-2021-31-4-55-63438Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of RabeprazoleO. D. Lopina0B. K. Nurgalieva1T. L. Lapina2Lomonosov Moscow State UniversityAsfendiyarov Kazakh National Medical University; KhAK Medical Centre LLPSechenov First Moscow State Medical University (Sechenov University)Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatment for such acid-dependent diseases as gastroesophageal reflux disease and peptic ulcer. This makes rabeprazole (Pariet) a preferred drug in course and maintenance therapies for acid-dependent diseases, as well as in H. pylori eradication.Conclusion. The rabeprazole properties of high acid suppression potential, persistent antisecretory effect from first day of therapy, non-enzymatic metabolism and pleiotropic action determine its high efficacy in treatment for a wide range of acid-dependent diseases at a minimal risk of drug interaction.https://www.gastro-j.ru/jour/article/view/638proton pump inhibitorsrabeprazolegastroesophageal reflux diseasepeptic ulcerh. pylori eradication therapysafetyproton pump inhibitor deprescribing |
| spellingShingle | O. D. Lopina B. K. Nurgalieva T. L. Lapina Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole Российский журнал гастроэнтерологии, гепатологии, колопроктологии proton pump inhibitors rabeprazole gastroesophageal reflux disease peptic ulcer h. pylori eradication therapy safety proton pump inhibitor deprescribing |
| title | Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole |
| title_full | Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole |
| title_fullStr | Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole |
| title_full_unstemmed | Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole |
| title_short | Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole |
| title_sort | current trends in treatment for acid dependent diseases clinical efficacy and safety of rabeprazole |
| topic | proton pump inhibitors rabeprazole gastroesophageal reflux disease peptic ulcer h. pylori eradication therapy safety proton pump inhibitor deprescribing |
| url | https://www.gastro-j.ru/jour/article/view/638 |
| work_keys_str_mv | AT odlopina currenttrendsintreatmentforaciddependentdiseasesclinicalefficacyandsafetyofrabeprazole AT bknurgalieva currenttrendsintreatmentforaciddependentdiseasesclinicalefficacyandsafetyofrabeprazole AT tllapina currenttrendsintreatmentforaciddependentdiseasesclinicalefficacyandsafetyofrabeprazole |